Citations

Showing 10 of 108162 citations.

Sensitivity analysis of the primary endpoint from the N-MOmentum study of inebilizumab in NMOSD
Cree, Bruce , Bennett, Jeffrey L. , Kim, Ho Jin , Weinshenker, Brian G. , Pittock, Sean J, Wingerchuk, Dean M. , Paul, Friedemann , Cutter, Gary , Marignier, Romain , Green, Ari , Aktaş, Orhan , Hartung, Hans-Peter, Williams, Ian M., Drappa, Jörn , She, Dewei, Cimbora, Daniel , Rees, William A. , Ratchford, John N. , Katz, Eliezer , Pittock, Sean J. , Kunchok, Amy , Cree, Bruce Ac , Pittock, Sean J , Wingerchuk, Dean, Pittock, S J , Bennett, Jeffrey L , Weinshenker, Brian G , Paul, Friedemann , Fujihara, Kazuo

Mayo Clinic

Multiple Sclerosis Journal | February 9, 2021 | Volume: 27 | Issue: 13 | Pages: 2052-2061

10.1177/1352458521988926 | PMID 33538237 Get It

Background: In the N-MOmentum trial, the risk of an adjudicated neuromyelitis optica spectrum disorder (NMOSD) attack was significantly reduced with inebilizumab compared with placebo. Objective: To demonstrate the robustness of this finding, using pre-specified sensitivity and subgroup analyses. Methods: N-MOmentum is a prospective, randomized, placebo-controlled, double-masked trial of inebilizumab, an anti-CD19 monoclonal B-cell-depleting antibody, in patients with NMOSD. Pre-planned and post hoc analyses were performed to evaluate the primary endpoint across a range of attack definitions and demographic groups, as well as key secondary endpoints. Results: In the N-MOmentum trial (ClinicalTrials.gov: NCT02200770), 174 participants received inebilizumab and 56 received placebo. Attack risk for inebilizumab versus placebo was consistently and significantly reduced, regardless of attack definition, type of attack, baseline disability, ethnicity, treatment history, or disease course (all with hazard ratios < 0.4 favoring inebilizumab, p < 0.05). Analyses of secondary endpoints showed similar trends. Conclusion: N-MOmentum demonstrated that inebilizumab provides a robust reduction in the risk of NMOSD attacks regardless of attack evaluation method, attack type, patient demographics, or previous therapy. The N-MOmentum study is registered at ClinicalTrials.gov: NCT2200770.
Atrial coupling index by standard echocardiography in degenerative mitral regurgitation: incremental determinant of survival
Antoine, Clémence , Batista, Roberta, Maalouf, Joseph F., Essayagh, Benjamin , Benfari, Giovanni , Michelena, Héctor I. , Enriquez‐Sarano, Maurice

Mayo Clinic

European Heart Journal - Cardiovascular Imaging | February 9, 2021 | Volume: 22 | Issue: Supplement_1 | Pages: No page available

10.1093/ehjci/jeaa356.087 Get It

Abstract Funding Acknowledgements Type of funding sources: Public hospital(s). Main funding source(s): Mayo Clinic Foundation Background Left atrial (LA) volume is linked to outcome in degenerative mitral regurgitation (DMR) but does not encompass LA function assessment. Thus, we ought to determine the prognostic role of left atrial coupling-index (LACI), as left atrial volume-index (LAVI) by Tissue-Doppler-Imaging a’ (TDI-a’), in a large cohort of DMR. Methods All consecutive 4792 patients (61 ± 16 years, 48% women) with isolated degenerative mitral valve disease diagnosed at Mayo Clinic 2003-2011, comprehensively characterized, in whom LAVI and TDI-a’ in sinus rhythm was prospectively measured in routine practice, was enrolled and their long-term survival analyzed. Results LACI (5.8 ± 3.7–T1 &lt; 3.8; T2 3.8-6.3; T3 &gt; 6.3) was significantly higher through different DMR grades (no, mild, moderate, severe DMR: 3.77 ± 2.26, 5.08 ± 2.95, 6.54 ± 3.74 and 7.84 ±4.29 respectively; p &lt; 0.0001). Independent determinants of LA dysfunction assessed by LACI were age, E/e’, left-ventricle (LV) end-systolic-diameter, mitral-regurgitation (MR) grade, and LV ejection-fraction (all P ≤ 0.0001). LACI &gt; 6 was independently associated with dyspnea, edema, more severe functional tricuspid-regurgitation and elevated pulmonary artery pressure, irrespective of age, sex, Charlson-comorbidity-index, ventricular function and MR severity. Total follow-up was 7.03 ± 3.0 years, during which 1146 (24%) underwent mitral-valve surgery (94% repair-6% replacement) and 880 (18%) died, 780 under medical treatment and 100 after surgery. Overall survival throughout follow-up (10-year 76 ± 1%) was strongly associated with LACI (88 ± 1% vs. 78 ± 1% and 62 ± 2% for LACI &lt;3.8, 3.8-6.3 and ≥6.3, P &lt; 0.0001) even adjusting comprehensively, including for DMR severity (adjusted-hazard-ratio 1.23[1.07-1.43] for LACI &gt; 5.79, P = 0.005). Mortality under medical management was profoundly affected by LACI (adjusted-hazard-ratio 1.11[1.05-1.18] per 3 unit increment; 1.35[1.15-1.58] for LACI &gt; 5.79 vs. ≤5.79, both P = 0.0002). Survival improved after mitral surgery (time-dependent adjusted-hazard-ratio 0.40[0.28-0.65], P &lt; 0.0001) but remained humbly linked to LACI (10-year 93 ± 3% vs. 90 ± 2% and 80 ± 3% for LACI tertiles, P = 0.0008). Most importantly, LACI provided incremental prognostic information over LAVI and other conventional determinants of survival (P &lt; 0.0001) with Net-reclassification-improvement vs. LAVI of 0.21 ± 0.02, P &lt; 0.0001. Conclusion LA function assessed by LACI in routine practice, by conventional echocardiographic measurements, displays incremental and independent link to excess-mortality, considerable under medical management and partially alleviated by mitral surgery. Thus, LACI is a simple tool of crucial interest in DMR risk-stratification. Abstract Figure. LACI in DMR
NCCN Guidelines Insights: Prostate Cancer, Version 1.2021
Schaeffer, Edward M. , Srinivas, Sandy, Antonarakis, Emmanuel S. , Armstrong, Andrew J. , Bekelman, Justin E. , Cheng, Heather H. , D’Amico, Anthony V. , Desai, Neil , Dorff, Tanya B. , Eastham, James A., Farrington, Thomas A., Gao, Xin , Horwitz, Eric M. , Kuettel, Michael, McKay, Rana R. , McKenney, Jesse K. , Netto, George J. , Pow‐Sang, Julio M. , Reiter, Robert E. , Richey, Sylvia, Roach, Mack , Rosenfeld, Stan, Shabsigh, Ahmad , Spratt, Daniel E. , Teply, Benjamin A. , Shead, Dorothy A. , Freedman-Cass, Deborah A., Antonarakis, Emmanuel S. , Davis, Brian J. , Spratt, Daniel E , Cheng, Heather H , Antonarakis, Emmanuel S , Teply, Benjamin A , Armstrong, Andrew J , Antonarakis, Emmanuel S , Ippolito, Joseph E. , Lang, Joshua M. , Penson, David F. , Tward, Jonathan D.

Mayo Clinic

Journal of the National Comprehensive Cancer Network | February 9, 2021 | Volume: 19 | Issue: 2 | Pages: 134-143

10.6004/jnccn.2021.0008 | PMID 33545689 Get It

The NCCN Guidelines for Prostate Cancer address staging and risk assessment after a prostate cancer diagnosis and include management options for localized, regional, and metastatic disease. Recommendations for disease monitoring and treatment of recurrent disease are also included. The NCCN Prostate Cancer Panel meets annually to reevaluate and update their recommendations based on new clinical data and input from within NCCN Member Institutions and from external entities. This article summarizes the panel’s discussions for the 2021 update of the guidelines with regard to systemic therapy for metastatic castration-resistant prostate cancer.
Body Mass Index and Weight Change in Patients With HER2-Positive Early Breast Cancer: Exploratory Analysis of the ALTTO BIG 2-06 Trial
Martel, Samuel , Agbor‐Tarh, Dominique, Pondé, Noam , Gombos, Andrea , Paterson, Vicki, Hilbers, Florentine , Korde, Larissa A. , Manukyants, Anna, Dueck, Amylou C. , Maurer, Christian , Piccart, Martine , Moreno‐Aspitia, Alvaro , Desmedt, Christine , Dueck, A. C. , Lambertini, Matteo , Cosimo, Serena Di , Azambuja, Evandro de

Mayo Clinic

Journal of the National Comprehensive Cancer Network | February 9, 2021 | Volume: 19 | Issue: 2 | Pages: 181-189

10.6004/jnccn.2020.7606 | PMID 33401235 Get It

Background: The association between obesity and prognosis in HER2-positive early breast cancer remains unclear, with limited data available. This study aimed to determine the impact of body mass index (BMI) at baseline and weight change after 2 years on outcomes of patients with HER2-positive early breast cancer. Methods: ALTTO was a randomized phase III trial in patients with HER2-positive early breast cancer. BMI was collected at randomization and 2 years after. WHO BMI categories were used: underweight, <18.5 kg/m2; normal weight, 18.5 to <25 kg/m2; overweight, ≥25 to <30 kg/m2; and obese ≥30 kg/m2. A weight change from baseline of ≥5.0% and ≤5.0% was categorized as weight gain and weight loss. The impact of BMI at randomization and of weight change on disease-free survival (DFS), distant disease-free survival (DDFS), and overall survival (OS) were investigated with multivariate analyses, adjusting for baseline patients and tumor characteristics. Results: A total of 8,381 patients were included: 187 (2.2%), 3,797 (45.3%), 2,690 (32.1%), and 1,707 (20.4%) were underweight, normal weight, overweight, and obese at baseline, respectively. Compared with normal weight, being obese at randomization was associated with a significantly worse DDFS (adjusted hazard ratio [aHR], 1.25; 95% CI, 1.04–1.50) and OS (aHR, 1.27; 95% CI, 1.01–1.60), but no significant difference in DFS (aHR, 1.14; 95% CI, 0.97–1.32). Weight loss ≥5.0% at 2 years after randomization was associated with significantly poorer DFS (aHR, 1.34; 95% CI, 1.05–1.71), DDFS (aHR, 1.46; 95% CI, 1.07–1.98), and OS (aHR, 1.83; 95% CI, 1.18–2.84). Hormone receptor and menopausal status but not anti-HER2 treatment type influenced outcomes. Toxicities were more frequent in obese patients. Conclusions: In patients with HER2-positive early breast cancer, obesity at baseline is a poor prognostic factor. Weight loss during treatment and follow-up negatively impacts clinical outcomes. Dietary counseling should be part of survivorship care programs.
Antithrombotic Therapy in Patients With Atrial Fibrillation Treated With Oral Anticoagulation Undergoing Percutaneous Coronary Intervention
Angiolillo, Dominick J. , Bhatt, Deepak L. , Cannon, Christopher P. , Goodman, Shaun G. , Granger, Christopher B. , Holmes, David R. , Lópes, Renato D. , Mehran, Roxana , Moliterno, David J. , Saw, Jacqueline , Tanguay, Jean-François, Faxon, David P., Mehran, Roxana , Lopes, Renato D , Bhatt, Deepak L , Angiolillo, Dominick J , Goodman, Shaun G , Granger, Christopher B , Eikelboom, John W. , Gibson, C. Michael , Price, Matthew J. , Tanguay, Jean‐François

Mayo Clinic

Circulation | February 8, 2021 | Volume: 143 | Issue: 6 | Pages: 583-596

10.1161/circulationaha.120.050438 | PMID 33555916 Get It

A growing number of patients undergoing percutaneous coronary intervention (PCI) with stent implantation also have atrial fibrillation. This poses challenges for their optimal antithrombotic management because patients with atrial fibrillation undergoing PCI require oral anticoagulation for the prevention of cardiac thromboembolism and dual antiplatelet therapy for the prevention of coronary thrombotic complications. The combination of oral anticoagulation and dual antiplatelet therapy substantially increases the risk of bleeding. Over the last decade, a series of North American Consensus Statements on the Management of Antithrombotic Therapy in Patients with Atrial Fibrillation Undergoing Percutaneous Coronary Intervention have been reported. Since the last update in 2018, several pivotal clinical trials in the field have been published. This document provides a focused updated of the 2018 recommendations. The group recommends that in patients with atrial fibrillation undergoing PCI, a non–vitamin K antagonist oral anticoagulant is the oral anticoagulation of choice. Dual antiplatelet therapy with aspirin and a P2Y 12 inhibitor should be given to all patients during the peri-PCI period (during inpatient stay, until time of discharge, up to 1 week after PCI, at the discretion of the treating physician), after which the default strategy is to stop aspirin and continue treatment with a P2Y 12 inhibitor, preferably clopidogrel, in combination with a non–vitamin K antagonist oral anticoagulant (ie, double therapy). In patients at increased thrombotic risk who have an acceptable risk of bleeding, it is reasonable to continue aspirin (ie, triple therapy) for up to 1 month. Double therapy should be given for 6 to 12 months with the actual duration depending on the ischemic and bleeding risk profile of the patient, after which patients should discontinue antiplatelet therapy and receive oral anticoagulation alone.
Clinical and echocardiographic characteristics of patients with pathology proven left-sided non-valvular papillary fibroelastoma
El‐Am, Edward , Ahmad, Ali , Kurmann, Reto , Sorour, Ahmed A. , Bois, Melanie C. , Maleszewski, Joseph J. , Klarich, Kyle W.

Mayo Clinic

European Heart Journal - Cardiovascular Imaging | February 8, 2021 | Volume: 22 | Issue: Supplement_1 | Pages: No page available

10.1093/ehjci/jeaa356.094 Get It

Abstract Funding Acknowledgements Type of funding sources: None. Background Papillary fibroelastoma (PFE) is now regarded as the most common primary tumor of the heart. Although benign, they are clinically significant for their high risk of embolization. They are most commonly found on cardiac valves but can also be present on non-valvular endocardial surfaces. The aim of this study was to better characterize patients with left-sided non-valvular PFE and its clinical sequelae. Methods We retrospectively identified patients with pathology-proven PFEs at a single center between January 1995 and December 2018 (n = 279). Patients with left-sided non-valvular PFE were analyzed. Medical records were retrospectively reviewed for clinical characteristics and outcomes. In addition, intra-operative transesophageal echocardiograms were manually reviewed to estimate overall size and location. Results During the study period, we identified 37 patients with left-sided non-valvular PFE (mean age 61 ± 14 years; 62% females) (Table). PFEs were located on the left ventricle in 41%, left atrium in 35%, and left ventricular outflow tract in 24% of patients. Around a quarter of patients (27%) had a diagnosis of hypertrophic cardiomyopathy, 19% had prior cardiac surgery, and 27% had cancer diagnosed prior to PFE diagnosis. Transient ischemic attack or stroke was the presenting symptom in 22% of patients, myocardial infarction in 6% and peripheral embolization in 6%. Median maximal length for PFE on the left ventricle was 11.1 mm [3;18], on the left atrium 9 mm [2;25], and left ventricular outflow tract 8 mm [6;13]. A minority of patients (9/37 [24%]) had associated valvular PFE on the mitral valve and/or aortic valve (1 patient had both mitral valve and aortic valve PFE, 7 had aortic valve PFE and 1 had Mitral valve PFE). Only 13 patients had follow up transthoracic/transesophageal echocardiogram 1 year after PFE removal; 4/13 (31%) had documented PFE recurrence (3 PFE recurred in the same location as the original; 1 in a different location). Conclusion Left-sided non-valvular PFE is associated with thromboembolic events and at least in those that had follow-up echocardiograms, had a high recurrence rate. More studies are needed to evaluate the management of patients with asymptomatic PFE. Abstract Figure. Baseline Characteristics
Ablation Versus Drug Therapy for Atrial Fibrillation in Heart Failure
Packer, Douglas L. , Piccini, Jonathan P. , Monahan, Kristi H. , Al‐Khalidi, Hussein R. , Silverstein, A , Noseworthy, Peter A. , Poole, Jeanne E. , Bahnson, Tristram D. , Lee, Kerry L., Mark, Daniel B. , Investigators, For the CABANA, Noseworthy, Peter A , Silverstein, Adam P , Mark, Daniel B , Investigators, For the CABANA

Mayo Clinic

Circulation | February 8, 2021 | Volume: 143 | Issue: 14 | Pages: 1377-1390

10.1161/circulationaha.120.050991 | PMID 33554614 Get It

Background: In patients with heart failure and atrial fibrillation (AF), several clinical trials have reported improved outcomes, including freedom from AF recurrence, quality of life, and survival, with catheter ablation. This article describes the treatment-related outcomes of the AF patients with heart failure enrolled in the CABANA trial (Catheter Ablation Versus Antiarrhythmic Drug Therapy for Atrial Fibrillation). Methods: The CABANA trial randomized 2204 patients with AF who were ≥65 years old or <65 years old with ≥1 risk factor for stroke at 126 sites to ablation with pulmonary vein isolation or drug therapy including rate or rhythm control drugs. Of these, 778 (35%) had New York Heart Association class >II at baseline and form the subject of this article. The CABANA trial’s primary end point was a composite of death, disabling stroke, serious bleeding, or cardiac arrest. Results: Of the 778 patients with heart failure enrolled in CABANA, 378 were assigned to ablation and 400 to drug therapy. Ejection fraction at baseline was available for 571 patients (73.0%), and 9.3% of these had an ejection fraction <40%, whereas 11.7% had ejection fractions between 40% and 50%. In the intention-to-treat analysis, the ablation arm had a 36% relative reduction in the primary composite end point (hazard ratio, 0.64 [95% CI, 0.41–0.99]) and a 43% relative reduction in all-cause mortality (hazard ratio, 0.57 [95% CI, 0.33–0.96]) compared with drug therapy alone over a median follow-up of 48.5 months. AF recurrence was decreased with ablation (hazard ratio, 0.56 [95% CI, 0.42–0.74]). The adjusted mean difference for the AFEQT (Atrial Fibrillation Effect on Quality of Life) summary score averaged over the entire 60-month follow-up was 5.0 points, favoring the ablation arm (95% CI, 2.5–7.4 points), and the MAFSI (Mayo Atrial Fibrillation-Specific Symptom Inventory) frequency score difference was –2.0 points, favoring ablation (95% CI, –2.9 to –1.2). Conclusions: In patients with AF enrolled in the CABANA trial who had clinically diagnosed stable heart failure at trial entry, catheter ablation produced clinically important improvements in survival, freedom from AF recurrence, and quality of life relative to drug therapy. These results, obtained in a cohort most of whom had preserved left ventricular function, require independent trial verification. Registration: URL: https://www.clinicaltrials.gov/ct2/show/NCT00911508 ; Unique identifier: NCT0091150.
Topical nonsteroidal anti-inflammatory drugs in the treatment of knee osteoarthritis: a systematic review and meta-analysis
Wolff, Dylan , Christophersen, Christy, Mulcahey, Mary K. , Wolff, Dylan G , Brown, Symone M.

Mayo Clinic

The Physician and Sportsmedicine | February 8, 2021 | Volume: 49 | Issue: 4 | Pages: 381-391

10.1080/00913847.2021.1886573 | PMID 33554694 Get It

Methadone, Metoclopramide and Metronidazole Interaction Causing Torsades de Pointes
Gnanapandithan, Karthik , Karthik, Nishrutha, Gerber, Jaime, Gnanapandithan, Karthik

Mayo Clinic

Clinics and Practice | February 8, 2021 | Volume: 11 | Issue: 1 | Pages: 101-105

10.3390/clinpract11010015 | PMID 33562182 Get It

There are several classes of medications that can cause prolongation of the corrected QT (QTc) interval and potentially Torsades de Pointes (TdP). Most of these medications are commonly used in the emergency department, and interaction between these medications increases the risk of this iatrogenic complication. We describe a patient on methadone therapy who developed TdP after she received metoclopramide and metronidazole. Interaction between different classes of medications can increase the risk of QTc prolongation and TdP. Awareness of this condition and its risk factors need continuous reinforcement among all hospital personnel to reduce the risk of this life-threatening complication.
Fast random algorithms for manifold based optimization in reconstructing 3D chromosomal structures
Chen, Duan, Li, Shaoyu , Xia, Kelin , Wang, Xue

Mayo Clinic

Communications in Information and Systems | February 8, 2021 | Volume: 21 | Issue: 1 | Pages: 1-29

10.4310/cis.2021.v21.n1.a1 Get It